Q-omics provides the consensus-scored RNA5SP239 profile across patient tissues and cancer cell-line models. RNA5SP239 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RNA5SP239 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, RNA5SP239 RNA expression shows 5,524 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, BRCA, and STAD as cancer lineages where RNA5SP239 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNA5SP239 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNA5SP239 survival associations across molecular data types. RNA5SP239 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNA5SP239 RNA expression–survival associations across cancer types. High RNA5SP239 expression shows unfavorable associations in LUAD, KIRC, BRCA, THCA, UCS and LIHC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for RNA5SP239 RNA expression.
This table summarizes RNA5SP239 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNA5SP239. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNA5SP239 shows lower tumor expression in BRCA. The BRCA box plot shows higher RNA5SP239 RNA expression in normal versus tumor tissue (log2 FC = −0.029, t-test p = .028).
This table shows molecular features associated with RNA5SP239 in patient tissues and cancer cell lines. In patient samples, RNA5SP239 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
